The invention belongs to the technical field of agricultural chemicals, and particularly relates to an N-(1,3,4-oxadiazol-2-yl)arylcarboxamide compound or a salt thereof, a preparation method, a herbicidal composition and a use thereof. The compound is as shown in the following Formula I:

##STR00001## wherein X represents O, S, SO, SO.sub.2 or NR.sub.1; Y represents halogen, cyano, cyanoalkyl, carboxyl, nitro, etc.; or —X—Y represents unsubstituted or substituted five- or six-membered heterocyclyl or heteroaryl; Z represents hydrogen, halogen, cyano, OR.sub.4, -alkyl-OR.sub.4, —O-alkyl-N(R.sub.5).sub.2, etc., M represents hydrogen, OR.sub.6, SR.sub.6, COR.sub.6, COOR.sub.6, CON(R.sub.7).sub.2, etc. The compound has advantages of a low dosage for use, excellent herbicidal activity, and higher crop safety, especially good selectivity for key crops such as rice.

Compounds, compositions and methods are provided for mitochondrial modulation. The subject mitochondrial modulator compounds generally include a head group linked to a charged moiety. In certain cases, the head group is a heterocyclic or a heteroaryl group. Aspects of the subject methods include a method of modulating mitochondria. Aspects of the subject methods include treating a subject having a metabolic syndrome-related disease or a symptom thereof by administering to the subject a therapeutically effective amount of a subject compound. In certain cases, the disease is selected from hyperlipidemia, type 2 diabetes, fatty liver disease, obesity, cardiovascular disease and stroke. In certain cases, the symptom is selected from abdominal obesity, insulin resistance, hyperinsulinemia, high levels of blood fats, increased blood pressure, and elevated serum lipids.

The invention discloses a tetramethyl-7,7′-spirobiindane-based phosphinooxazoline ligand compound and its preparation method and use. The phosphinooxazoline ligand compound is a compound having a structure shown in general formula I or an enantiomer, a raceme or a diastereoisomer thereof. The phosphinooxazoline ligand obtained through a series of reaction steps using cheap and easily available 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-6,6′-diol as a starting material. The novel phosphinooxazoline ligand developed in the invention can be used to organic catalytic reactions, especially as a chiral phosphinooxazoline ligand widely used in metal-asymmetric catalytic reactions, having economical practicality and industrial application prospects. ##STR00001##

The invention discloses a tetramethyl-7,7-spirobiindane-based phosphinooxazoline ligand compound and its preparation method and use. The phosphinooxazoline ligand compound is a compound having a structure shown in general formula I or an enantiomer, a raceme or a diastereoisomer thereof. The phosphinooxazoline ligand obtained through a series of reaction steps using cheap and easily available 3,3,3,3-tetramethyl-1,1-spirobiindane-6,6-diol as a starting material. The novel phosphinooxazoline ligand developed in the invention can be used to organic catalytic reactions, especially as a chiral phosphinooxazoline ligand widely used in metal-asymmetric catalytic reactions, having economical practicality and industrial application prospects.

##STR00001##

The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

A composition comprising a perfluoro-N.sup.2-phosphinylamidine chromium salt complex having Structure PFAHNPACr I: ##STR00001##
wherein R.sup.f1 is a substituted phenyl group comprising alkyl groups at the 2 and 6 positions and at least one fluoro group or perfluoroalkyl group at the 3, 4, and/or 5 positions, R.sup.2 is a C.sub.1 to C.sub.30 organyl group, R.sup.4 and R.sup.5 are each independently a C.sub.1 to C.sub.30 organyl group, and CrX.sub.p is a chromium salt where X is a monoanion, and p is an integer from 2 to 6.

The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.

A composition comprising a perfluoro-N.sup.2-phosphinylamidine chromium salt complex having Structure PFAHNPACr I:

##STR00001##

wherein R.sup.f1 is a substituted phenyl group comprising alkyl groups at the 2 and 6 positions and at least one fluoro group or perfluoroalkyl group at the 3, 4, and/or 5 positions, R.sup.2 is a C.sub.1 to C.sub.30 organyl group, R.sup.4 and R.sup.5 are each independently a C.sub.1 to C.sub.30 organyl group, and CrX.sub.p is a chromium salt where X is a monoanion, and p is an integer from 2 to 6.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

##STR00001##